Weiyu Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Weiyu Hu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Dimin Zhu
Department of Neurosurgery, Pituitary Tumor Center, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
1 shared publicationDong Fan
Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China
1 shared publication- Dongsheng He
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication Jiaming Wang
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publicationQing Rao
Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
1 shared publicationShun Yao
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
1 shared publication
Latest Publications
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 160
Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis
Objective To assess the differences in clinicopathological features and outcomes of non-functioning pituitary neuroendocrine tumors (PitNETs) based on transcription factor expression. Methods Clinical data were collected from patients diagnosed with non-functioning PitNETs at our hospital. Tumors were classified into transcription factor-based subgroups for comparison. Clinical characteristics were analyzed across these subgroups, and prognostic data were obtained through postoperative outpatient records and telephone follow-ups. Results A total of 409 patients were included, comprising 202 males (49.4%) and 207 females (50.6%). Of these, 245 (59.9%), 101 (24.7%), 39 (9.5%), and 24 (5.9%) patients were classified into the steroidogenic factor-1 (SF1), T-box transcription factor 19 (TPIT), POU class 1 homeobox 1 (PIT1), and no distinct lineage groups, respectively. The SF1 subgroup was associated with lipid metabolism disorders. The TPIT subgroup had the largest and most invasive tumors. Patients in the PIT1 and no distinct lineage groups were more likely to present with hyperprolactinemia and galactorrhea and showed a lower tendency to invade the cavernous sinus. The median follow-up duration was 801 days. The PIT1 and TPIT subgroups had shorter tumor-free survival, particularly the former. Further survival analysis revealed that patients with TPIT and PIT1 lineages had poorer prognoses. Conclusions Transcription factor expression was associated with distinct clinical features and short-term outcomes. The PIT1 and TPIT lineages were linked to shorter tumor-free survival. Enhanced postoperative surveillance is recommended for these subgroups. These findings underscore the clinical and prognostic heterogeneity of non-functioning PitNETs.
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 160
Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis
Objective To assess the differences in clinicopathological features and outcomes of non-functioning pituitary neuroendocrine tumors (PitNETs) based on transcription factor expression. Methods Clinical data were collected from patients diagnosed with non-functioning PitNETs at our hospital. Tumors were classified into transcription factor-based subgroups for comparison. Clinical characteristics were analyzed across these subgroups, and prognostic data were obtained through postoperative outpatient records and telephone follow-ups. Results A total of 409 patients were included, comprising 202 males (49.4%) and 207 females (50.6%). Of these, 245 (59.9%), 101 (24.7%), 39 (9.5%), and 24 (5.9%) patients were classified into the steroidogenic factor-1 (SF1), T-box transcription factor 19 (TPIT), POU class 1 homeobox 1 (PIT1), and no distinct lineage groups, respectively. The SF1 subgroup was associated with lipid metabolism disorders. The TPIT subgroup had the largest and most invasive tumors. Patients in the PIT1 and no distinct lineage groups were more likely to present with hyperprolactinemia and galactorrhea and showed a lower tendency to invade the cavernous sinus. The median follow-up duration was 801 days. The PIT1 and TPIT subgroups had shorter tumor-free survival, particularly the former. Further survival analysis revealed that patients with TPIT and PIT1 lineages had poorer prognoses. Conclusions Transcription factor expression was associated with distinct clinical features and short-term outcomes. The PIT1 and TPIT lineages were linked to shorter tumor-free survival. Enhanced postoperative surveillance is recommended for these subgroups. These findings underscore the clinical and prognostic heterogeneity of non-functioning PitNETs.